Data demonstrated that vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA as a treatment for anemia due to chronic kidney disease when administered three times a week at the time of dialysis
Vadadustat demonstrated a similar safety profile to long-acting ESA when used three times a week
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.